Low-Level Zoonotic Transmission of Clade C MERS-CoV in Africa: Insights from Scoping Review and Cohort Studies in Hospital and Community Settings
- PMID: 39861917
- PMCID: PMC11768526
- DOI: 10.3390/v17010125
Low-Level Zoonotic Transmission of Clade C MERS-CoV in Africa: Insights from Scoping Review and Cohort Studies in Hospital and Community Settings
Abstract
Human outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) are more common in Middle Eastern and Asian human populations, associated with clades A and B. In Africa, where clade C is dominant in camels, human cases are minimal. We reviewed 16 studies (n = 6198) published across seven African countries between 2012 and 2024 to assess human MERS-CoV cases. We also analyzed data from four cohort studies conducted in camel-keeping communities between 2018 and 2024 involving camel keepers, camel slaughterhouse workers, and hospital patients with acute respiratory illness (ARI). The analysis showed a pooled MERS-CoV prevalence of 2.4% (IQR: 0.6, 11.4) from 16 publications and 1.14% from 4 cohort studies (n = 2353). Symptomatic cases were rarely reported, with most individuals reporting camel contact, and only 12% had travel history to the Middle East. There was one travel-associated reported death, resulting in a mortality rate of 0.013%. The findings suggest a low camel-to-human transmission of clade C MERS-CoV in Africa. Ongoing research focuses on genomic comparisons between clade C and the more virulent clades A and B, alongside the surveillance of viral evolution. This study highlights the need for continuous monitoring but indicates that MERS-CoV clade C currently poses a minimal public health threat in Africa.
Keywords: MERS-CoV; camel; clades; epidemiology; infections; prevalence; serology; symptoms; transmission; zoonotic.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Development and preliminary validation of a MERS-CoV ELISA for serological testing of camels and alpacas.J Virol Methods. 2024 Jun;327:114923. doi: 10.1016/j.jviromet.2024.114923. Epub 2024 Mar 30. J Virol Methods. 2024. PMID: 38561124
-
Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.Emerg Infect Dis. 2025 Jan;31(1):57-65. doi: 10.3201/eid3101.241030. Epub 2024 Dec 6. Emerg Infect Dis. 2025. PMID: 39641462 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018.Euro Surveill. 2019 Nov;24(48):1900244. doi: 10.2807/1560-7917.ES.2019.24.48.1900244. Euro Surveill. 2019. PMID: 31796154 Free PMC article.
Cited by
-
Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses.Front Microbiol. 2025 Jul 16;16:1593095. doi: 10.3389/fmicb.2025.1593095. eCollection 2025. Front Microbiol. 2025. PMID: 40740328 Free PMC article.
References
-
- Giovanetti M., Branda F., Cella E., Scarpa F., Bazzani L., Ciccozzi A., Slavov S.N., Benvenuto D., Sanna D., Casu M., et al. Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2. J. Med. Virol. 2023;95:e29012. doi: 10.1002/jmv.29012. - DOI - PubMed
Publication types
MeSH terms
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Medical